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Patients with Henoch-Schönlein purpura are sometimes referred for a general surgical opinion because of abdominal pain or gastrointestinal bleeding. Surgical intervention is seldom needed.
CASE HISTORY
A man of 41 was admitted by the medical team with a 4-day history of a purpuric rash covering his legs and buttocks, oedema of the ankles and wrists, generalized arthralgia, abdominal pain, rectal bleeding and vomiting. He was dehydrated and tachycardic; his abdomen was distended but non-tender; bowel sounds were absent; inflamed rectal mucosa was seen by rigid sigmoidoscopy. No free intraabdominal gas was evident on plain abdominal and chest radiography. These findings were consistent with the diagnosis of ileus secondary to a generalized vasculitis. After two days of conservative management the patient became oliguric and developed proteinuria with deteriorat-ing renal function. Parenteral steroid therapy was instituted and renal and skin biopsies were taken which subsequently confirmed the diagnosis of Henoch-Schönlein purpura (HSP). 4 days after admission his abdominal pain worsened and he developed tenderness with guarding in the right iliac fossa. Laparotomy disclosed hyperaemic small bowel, 2 litres of ascitic fluid and 45 cm of infarcted ileum. The infarcted bowel was resected, a double-barrelled ileostomy was formed and the patient was nursed in the intensive care unit for 48 hours. The ileostomy produced up to 7 litres of fluid per day, requiring careful fluid management; over 6 months the patient had to be readmitted intermittently for rehydration. Steroids were stopped after 9 months and the stoma was closed 3 months later; he subsequently made a good recovery. COMMENT HSP is rare in adults; less than one-third of patients with HSP admitted to hospital are over 20. Typically, an acute phase is followed by intermittent relapses in the following months. The aetiology is unclear and bacteria, viruses, vaccines, drugs, foods and exposure to cold have all come under suspicion. The clinical manifestations are due to deposition of IgA immune complexes on the intima of small blood vessels, leading to complement activation, leukocyte recruitment and destruction of endothelial cells. Skin biopsy reveals a leukocytoclastic vasculitis with necrotic vessel walls containing neutrophils surrounded by fibrin strands.
Abdominal symptoms in HSP are caused by haemorrhage and oedema within the bowel wall and mesentery. They occur in up to 56% of adults and are the presenting feature in 15% 1 . Pain is typically colicky and poorly localized, sometimes accompanied by vomiting and bloody diarrhoea. In adults, surgical intervention is seldom necessary 2 , whereas in children HSP is complicated by intussusception (2%), perforation (0.5%) and infarction (0.5%). Only one adult case of intestinal infarction secondary to HSP has been reported to our knowledge; that patient died 3 .
Early involvement of the surgical team, enabling them to make frequent clinical assessments of the patient and identify deterioration, is probably the best way to avoid abdominal catastrophes in HSP. Interferon-alpha treatment is associated with autoimmune thyroid dysfunction 1,2 . Antibody to thyroxine (T4) can confuse the interpretation of thyroid function tests 3 .
A woman of 24 was referred with suspected hypothyroidism. For twenty months she had been receiving interferon-alpha for chronic myelogenous leukaemia. A check on thyroid function four months into treatment had shown thyroid-stimulating hormone (TSH) 7.12 mIU/L (normal range 0.3-4.0) and free T4 15.4 pmol/L (10. 2-19.6) . At sixteen months she noted facial puffiness and weight gain, at which time TSH was 4150 mIU/L. Her symptoms partly subsided on treatment with L-thyroxine 50 mg daily. At the time of referral, TSH was 4150 mIU/L but she also had raised free T4 at 20.4 pmol/L. Antimicrosomal antibody titre was 6400; antithyroglobin was negative. In view of the improvement of symptoms and the inconsistent thyroid function test results, L-thyroxine was temporarily stopped and the tests were repeated. TSH remained 4150 mIU/L with a free T4 of 20.8 pmol/L. The simultaneous free T3 concentration was 2.3 pmol/L (normal range 3.5-6.5 pmol/L) and the erythrocyte zinc concentration was 334 mmol/L (155-237). Thus all biochemical results were consistent with primary hypothyroidism except for the high free T4. A two-step free T4 assay was arranged and she was given L-thyroxine 100 mg daily. On this dose the TSH fell to 52.5 mIU/L while the free T3 rose to 3.2 mIU/L. The free T4 result obtained with the two-step assay was later reported as 7.67 pmol/L, suggesting that T4 antibody had interfered with the onestep analogue assay. L-thyroxine was then gradually titrated down to 50 mg daily, on which dose TSH was 2.7 mIU/L while the free T4 result with the one-step assay was 19.5 pmol/L. Her thyroid function tests remained stable thereafter.
COMMENT
Interferon-alpha has been widely used in chronic myelogenous leukaemia 2 , and various endocrine diseases have been reported in association with this treatment 4 . In a series of 581 patients with chronic myelogenous leukaemia treated with interferon-alpha, 2% became hypothyroid 2 . Development of autoantibodies alone is much more common, reaching 20% in some series 5 . Thyroid dysfunction may be more prevalent in those who are antibodypositive before treatment. On withdrawal of interferon, the antibodies sometimes disappear and sometimes persist 1 .
Anti-T4 antibodies are well-known to account for a spuriously high free T4 result in the one-step analogue assay. The underlying mechanism is binding of the T4 analogue by antibody 3 . Antibodies are present in less than 1% of normal individuals 6 . Our patient had a normal free T4 three months after starting interferon, so she is unlikely to have had pre-existing T4 antibody. A causal relation is further indicated by the disappearance of T4 antibody when interferon treatment was stopped.
